|
|
|
- いとは ますはら
- 5 years ago
- Views:
Transcription
1 0774 CAS No
2
3
4 0774
5
6
7
8 F344/DuCrlCrlj ppm 200 ppm 200 ppm 200 ppm 200 ppm F344/DuCrlCrlj
9 (ppm) C Peto Cochran- Armitage (ppm) Peto Cochran- Armitage C * * C % * : p0.05 ** : p0.01 Fisher : p0.05 : p0.01 Peto, Cochran-Armitage : p0.05 : p0.01 Cochran-Armitage -2-
10 1 11 Ethylene glycol monoethyl ether acetate IUPAC 2-2-Ethoxyethyl acetate CAS No CH3-COO-CH2CH2-O-CH2CH torr20 23g/100g20 2 EPF DCM TLN () %() -3-
11 3 31 () M-80B() FTIR-8200PC 2 3 APPENDIX A APPENDIX () 795 F344/DuCrlCrlj SPF g89102g F344/DuCrlCrlj SPF -4-
12 ppm v/v OECD ppm ppm 87% 83%400 ppm 200 ppm -5-
13 90% 92% 90% 200 ppm ppm ppm 200 ppm 5012 ppm 4 16 () 17 () GC-14B 15 TABLE A % -6-
14 ppm ppm ppm APPENDIX % % % 5020% -7-
15 1 12 (8:0020:00)12 (20:008:00) Pa 5 340(W)294(D)176(H) mm/ (W)216(D)176(H) mm/ 5 150(W)216(D)176(H) mm/ 2 () 8-2 CRF-1 30kGy- () 3 ()
16 EDTA-2 APPENDIX 3 (MCV) (MCH)(MCHC) 35 APPENDIX 3 A/G ASTALTLDHALP-GTPCK ph -9-
17 % ppm g 1 g g
18 APPENDIX 3 42 Bartlett Dunnett Kruskal-Wallis Dunnett Peto 9Cochran-Armitage Fisher Peto () %Peto Fisher 5% 1% Peto
19 1 TABLE B 1, 2 FIGURE 1, %12 ppm 40 80%50 ppm 43 86% 200 ppm 47 94% %12 ppm 40 80%50 ppm 40 80% 200 ppm 42 84% 2 TABLE C 1, 2 3 TABLE D 14 FIGURE 3, ppm ppm 98%50 ppm 97% 200 ppm 94% 200 ppm ppm 97%50 ppm 96% 200 ppm 93% -12-
20 4 TABLE E 14 FIGURE 5, ppm 200 ppm 5 TABLE F 1, 2 MCV MCH 200 ppm 200 ppm 200 ppm other 200 ppm 6 TABLE G 1, 2 -GTP 200 ppm 50 ppm 200 ppm LDH 200 ppm 50 ppm 200 ppm 7 TABLE H 1, 2 ph 200 ppm -13-
21 8 81 TABLE I TABLE J 1, 2 TABLE K 1, ppm 200 ppm 200 ppm 50 ppm 200 ppm 12 ppm 83 TABLE L 16 TABLE M 1, 2 TABLE N 1, 2 Peto Cochran-Armitage Fisher TABLE O 1, 2 TABLE P 1, ppm 200 ppm -14-
22 200 ppm 2 12 ppm C 200ppm 1 Cochran-Armitage Fisher 200 ppm Cochran-Armitage Fisher 200 ppm Fisher 200 ppm ppm 200 ppm 200 ppm 84 TABLE Q 1, 2-15-
23 ppm ppm 12 ppm 98%50 ppm 97% 200 ppm 94% 12 ppm 97%50 ppm 96% 200 ppm 93% 200 ppm 200 ppm 2 IARC 10 10% NCI 11 10% Maximum Tolerated Dose (MTD) 200 ppm 94% 93% 200 ppm MTD -16-
24 3 -GTP 200 ppm 50 ppm 200 ppm LDH 200 ppm 50 ppm 200 ppm ph 200 ppm 200 ppm 50 ppm 200 ppm 200 ppm 200 ppm 200 ppm 200 ppm ppm ppm 400 ppm 100 ppm 200 ppm 50 ppm
25 IARC ( 17)Slesinski 18 TA98TA100 TA102TA104TA1535TA1537 WP2uvrAWP2uvrA/pKM g/plate S9 Slesinski Ames CHO HGPRT CHO SCESwiss-Webster CHO S9 CHO in vitro in vivo in vitro -18-
26 F344/DuCrlCrlj
27 1. ACGIH Ethoxyethyl Acetate. Documentation of the Threshold Limit Values and Biological Exposure Indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. [CD-ROM 2007]. 2. McLafferty FW, ed Wiley Registry of Mass Spectral Data. 6th ed. New York, NYJohn Wiley and Sons. 3. () , OECD OECD Guideline for Testing of Chemicals 451 "Carcinogenicity Studies". Paris: Organisation for Economic Co-operation and Development : : Nagano K, Katagiri T, Aiso S, Senoh H, Sakura Y, Takeuchi T Spontaneous lesions of nasal cavity in aging F344 rats and BDF1 mice. Exp Toxic Pathol. 49: Peto R, Pike MC, Day NE, Gray RG, Lee PN, Parish S, et al Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. Lyon: IARC. IARC Monographs Suppl 2: Bannasch P, Griesemer RA, Anders F, Becker R, Cabral JR, Della Porta G, et al Long-term assays for carcinogenicity in animals. In: Long-Term and Short-Term -20-
28 Assays for Carcinogens: A Critical Appraisal. (Montesano R, Bartsch H, Vainio H, Wilbourn J, Yamasaki H. eds.). Lyon: IARC. IARC Scientific Publications No. 83: Sontag JM, Page NP, Saffiotti U Guidelines for carcinogene bioassay in small rodents. NCI-CG-TR-1. DHEW Publication No.(NIH) Bethesda,MD: National Cancer Institute Nagano K, Katagiri T, Aiso S, Senoh H, Sakura Y, Takeuchi T Spontaneous lesions of nasal cavity in aging F344 rats and BDF1 mice. Exp Toxic Pathol. 49: Buckley LA, Morgan KT, Swenberg JA, James RA, Hamm TE Jr, Barrow CS The toxicity of dimethylamine in F-344 rats and B6C3F1 mice following a 1-year inhalation exposure. Fundam Appl Toxicol. 5: Monticello TM, Morgan KT, Uraih L Nonneoplastic nasal lesions in rats and mice. Environ Health Perspect. 85: Renne R, Brix A, Harkema J, Herbert R, Kittel B, Lewis D, March T, Nagano K, Pino M, Rittinghausen S, Rosenbruch M, Tellier P, Wohrmann T Proliferative and nonproliferative lesions of the rat and mouse, respiratory tract. Toxicol Pathol 37: 5S-73S. 16. Wolf DC, Morgan KT, Gross EA, Barrow C, Moss OR, James RA, et al Two-year inhalation exposure of female and male B6C3F1 mice and F344 rats to chlorine gas induces lesions confined to the nose. Fundam Appl Toxicol. 24: Slesinski RS, Guzzie PJ, Tyler TR Cytotoxicity and genotoxic potential of ethylene glycol monoethyl ether acetate (EGEEAc) in a battery of short term test systems. Environ Mol Mutagen, 11 Suppl 11:
29 -22-
t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph
2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa
1 200117 21512 CAS 111693 110 NC(CH 2 ) 4 CN 1,4- C 6 H 8 N 2 108.14 1 99 2-1. 2 1 295 159 c.c. 550 3 1.7-4.9 20 d 0.965 4 3.73 = 1 0.3 Pa 0.002 mmhg20 2 log Pow-0.32 m/z 41, 1.0 68 0.54 54 0.43 4 Koc9-16
CAS H 3 C C CH 2 C 9 H tert d = hpa
1 200140 35 CAS 98839 1335-2- H 3 C C CH 2 C 9 H 10 118.18 1 99 4-tert- 1. 2-23.2 2 163164 2 54 574 3 0.96.6 20 d 4 0.9082 2 4.07 = 1 2.5 hpa 1.9 mmhg20 2 4 log Pow3.48 3.44 m/z 118, 1.0 103 0.58 91 0.21
98-02.PDF
1 982 2207 CAS 67630 2- H 3 C H 3 C CH OH C 3 H 8 O 60.10 1 99.9 % n- 1. 2-88.5 3 82.5 3 11.7c.c. 455 4 212 d 20 4 0.78505 3 2.1 = 1 4 4.4 kpa 33 mmhg20 4 log Pow0.05 0.07 5 m/z45, 1.0 43 0.19 27 0.17
CAS O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) % 2- A BHT , 4
2-1 9628 31307 CAS 117817 2- O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O 4 390.56 CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) 3 1 99 % 2- ABHT 1. 2-55 3 3, 4 386 171 350 6 0.1 % d 20 4 0.9861 4 13.48 0.30410-4 Pa 2.2810-7
橡99-24_00 アリルアルコール.PDF
1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log
DCHP
2. 2 1. 1) 2) 2 Crj:CD(SD)IGS SPF 0 240 1200 6000 ppm 2 F0 10 F0 10 F1 21 F1 3 10 F1 3 10 F2 21 0 240 1200 6000 ppm 1 F0 0 15.88 79.57 401.8 mg/kg/day F0 0 20.80 104.19 510.7 mg/kg/day F1 0 17.84 89.89
橡フタル酸ブチルベンジル.PDF
1 97 7 3 1312 CAS 85 68 7 O BBP 1, 2- C 19 H 20 O 4 312.4 C C O O O (CH 2 ) 3 1 99.9 % 1. 2-35 3 2, 3 370 3, 4 199 d 25 4 1.117 2 10.8 = 1 5 1.15 10-3 Pa 8.6 10-6 mmhg 20 5 253 Pa 1.9 mmhg 200 5 log Pow
橡96-07.PDF
1 967 2482 CAS 50000 CH 2 O 30.03 2952% 12.5 % 1. 2) -92 2) -19.5 2) 5085 3) 424 3) 7.073.0% 4) 20 d 4 0.815 5) 1.03 ( = 1) 5) 1.33 kpa (10 mmhg) (-88.0) 2) log Pow0.35 ( ) 6) 0.35 ( ) 7) 1) m/z 29 ( 1.0
橡アジポニトリル.PDF
1 200117 21512( ) CAS 111693 110( ) 1,4- NC(CH 2 ) 4 CN C 6 H 8 N 2 108.14 1) 99 2-1. 2) 1 2) 295 2) 159(c.c.) 3) 550 3) 1.7-4.9 vol % ( ) 3) d 20 0.965 2) 3.73 ( = 1) 4 0.3 Pa (0.002 mmhg) (20) 2) log
,161 t 9,753 t 2,408 t LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum 6 3 Selenastrum h, Sb
1 20017 1543 CAS 1309644 125 Sb 2 O 3 291.52 1 99 1. 2 655 1,425 2 2 2 3 5.2 5.67 2 2 2. 10 12,161 t 9,753 t 2,408 t 4 3. 1 2 3 4. LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
橡96-01.PDF
1 961 31 CAS 71432 C 6 H 6 78.11 1) 99 % 1. 5.5 2) 80.1 2) -11 3) 293563 3) 1.48.0% 3) d 20 0.8786 4) 2.77 ( = 1) 4) 4 13.33 kpa (100 mmhg) (26.9) 2) log Pow2.13 ( ) 5) 2.14 ( ) 6) m/z78 ( 1.0 )77 ( 0.20
3, ,104 t mg/l 30 mg/l BOD mg 14 C 8, /kg 11 8, 1 11 OH = cm 3 / sec 11 OH /cm ppm
3, 3-1 200019 4800 CAS 91941 1138 3, 3-4, 4 - -3, 3 - H 2 N Cl Cl NH 2 C 12 H 10 C l2 N 2 253.13 1 95 1. 2 3, 4 132-133 402 5 >200 5 700kg/m 3 5 8.73 = 1 5.610-8 kpa 4.210-7 mmhg20 4 6 log Pow3.51 3.57
橡三酸化二アンチモン.PDF
1 2001 7 1 543( ) CAS 1309 64 4 1 25 ( ) Sb 2 O 3 291.52 1) 99 1. 2) 655 3) 1,425 3) ( ) 2) ( ) 2) ( ) 2) 5.2 ( ) 5.67 ( ) 3) 2) 2. 10 12,161 t ( 9,753 t 2,408 t) 4 2 1) 3. 1) 2) 3) 4. Selenastrum capricornutum
PREFACE The tests were contracted and supported by the Ministry of Labour of Japan. The tests were conducted by Japan Bioassay Laboratory (JBL) and th
Summary of Feeding Carcinogenicity Study of 1-Chloro-2,4-Dinitrobenzene in BDF 1 Mice August 1992 Japan Bioassay Laboratory Japan Industrial Safety and Health Association PREFACE The tests were contracted
初期リスク評価報告書作成指針（案）
BCF: Bioconcentration Factor EC 50 : Median Effect Concentration 1 50 EEC: Estimated Environmental Concentration EHI: Estimated Human Intake EUSES: Europian Union System for the Evaluation of Substances
化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]
![化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]](/thumbs/39/20157433.jpg "化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]")
1,3-1,3- (1) 1,3-1,3- - CAS 542-75-6 C 3 H 4 Cl 2 110.97 2 1) -84 2) 108 2,3) 112 (trans-) 4) 104 (cis-) 4) 1.225 (20 ) 2) 5.2 kpa (39 mmhg) (25 ) 2) 4.5 kpa (34 mmhg) (25 ) 4) 5.7 kpa (43 mmhg) (25 )
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
参考資料５ 農薬評価書 メタアルデヒド（食品安全委員会資料）
1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1
化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]
![化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]](/thumbs/104/163316306.jpg "化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]")
(1) CAS 302-01-2 N 2 H 4 32.0 CAS 7803-57-8 2 1) 2.0 2,3) 113.5 2,4) 1.011 (15 ) 2,3) 1.0036 (25 ) 2,4) 2.1 kpa (16 mmhg) (20 ) 3) 1ppm=1.31 mg/m 3 at 25, n- / -1.37 ( ) 3) 5) K b1 8.510-7 K b2 8.910-16
http://www.who.int/ipcs/publications/ehc/en/index.html EHC 1 2 3 4 / EHC http://www.nihs.go.jp/dcbi/publist/ehchsg/ 1-8) WHO/IPCS CICAD (Concise Inter
3 [ ] Priority IARC JMPR 2004 10 Priority 1 Priority 1 Priority 2 Priority 3 Priority 1 1-1) CERI) http://www.cerij.or.jp/ceri_jp/koukai/sheet/sheet_indx4.htm http://www.safe.nite.go.jp/data/sougou/pk_list.html?table_name=hyoka&rank=sh
02スチレンダイマー、トリマー.PDF
[Styrene dimer, CAS No. 25247-68-1; Styrene trimer, 28213-80-1] -1,2 C 16 H 16 C 24 H 24 208.2 312.3 4 7 2-1,2 CH 2 CH 2 2,4- -1-2,4,6- -1-1,2-1,3,5-760 21,430 g/g 9,590 g/g 2 3 HSDB, 2001 ; 2, 1998; 3
繁殖性に及ぼす影響
5. 2 1. (DEP) 1) DEP 2) 3) 4) DEP 0 600 3000 15000 ppm(0 43 210 1083 mg/kg/day 0 54 261 1336 mg/kg/day ) 24 Crj:CD(SD) IGS 2 DEP 15000 ppm F0 0-21 F1 F0 F1 DEP F1 F1 15000 ppm 15000 ppm F0 F1 F0 F0 P-450
040202PC用.doc
15 48 15 8 25 15 1321 15 8 25 0825002 15 8 25 6 8 15 2 18 15 6 27 2 15 3 13 28 35 (1) 51 198 7 (2) 3 6 1 100g (1) 1 (1) 1 2 1 astaxanthin;3,3 -dihydroxy-, -carotene-4,4 -dione (2) 1 2 C40H52O4 596.86 97.0
Mantel-Haenszelの方法
Mantel-Haenszel 2008 6 12 ) 2008 6 12 1 / 39 Mantel & Haenzel 1959) Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Nat. Cancer Inst. 1959; 224):
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
ｽﾗｲﾄﾞ ﾀｲﾄﾙなし
2003.11.25 JEMS/BMS 2 N H C C C NH 2 Furylfuramide (AF-2) Dibenzo[a, l ]pyrene ( DBP) PAH Mutant Frequencies of lacz and cii gene Induced by DBP and AF2 600 500 400 cii lacz cii lacz 300 200 100 0 Liver
（Ⅱ）化学物質の環境リスク初期評価（13物質）の結果
1 ( ) DBDPO CAS 1163-19-5 C 12 Br 10 O 959.2 2 1) 305 2) 3.0 1) 1- / (logp ow ) 1) 5.03 mmhg306 1) 1) 3) 4) 5) 1.010-4 6) mg/l25 3 7) OH 8) 4 9) 6 BOD 0% 14 100 mg/l 30 7) 10) BCF 5 < 42 60 mg/l 7) 50
資料１(目消し版).ppt
1 Dr. Grandjean 2 15 45 3 4 CH 3 Hg + Hg 0 fi Hg ++ fich 3 + MeHg MeHg 5 Methylmercury-2 6 :, A. Yasutake 7 - A. Yasutake 8 :,. A. Yasutake 9 A. Yasutake 10 (%) : : : : : MeHg 0.05 250 : 2 : 1 : 0.1 :
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
01オクタクロロスチレン.PDF
[Octachlorostyrene, CAS No. 29082-74-4] ( ) OCS C 8 C l8 379.71 0.0018 Pa (25 ) Log Pow = 6.29 ( ) 2) 0.00174 mg/l (25 ) HSDB, 2001; 2 PHYSPROP, 2000. 1 1. 1) (OCS) 9 OCS OCS 75 4 Selden et al., 1997 2
化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]
![化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]](/thumbs/39/20150687.jpg "化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]")
(1) 1,2- DMP CAS 131-11-3 C 10 H 10 O 4 194.2 2 1) 5.5 2,3) 283.7 2,3) 1.192 (20 ) 4) 133 Pa (1 mmhg) (20 ) 5) 1ppm=7.94 mg/m 3 at 25, n- / 1.56 ( ) 6) 4) ( )3.2 (30 ph 7)11.6 (30 ph 9)25 (18 ph 9) 5)
1 ( 2)
2016 1 24 1. 10km 2. 1 50g 1 3. 1 4. 1mSv 5. 2 (0 ) 1 1 (http://www.itarda.or.jp/materials/statistical.php) (http://www.airia.or.jp/number/) 1 1 km 0.1691 1 1) 2) () ( km) (/ km) 2008 725 3847 0.1884 2009
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
CSR報告書2005 (和文)
A 250 200 150 100 50 0 25,000 20,000 15,000 10,000 5,000 0 1,000 800 600 400 200 0 168 14 14 27 54 60 2000 16,975 1,314 1,207 8,977 5,477 2000 698 112 115 292 178 2000 223 24 28
ブック 1.indb
21 1211 27 11 27 12 16 20 11 27 10 20 28 29 30 12 10 11 12 30 13 30 14 10 30 15 11 16 12 17 13 18 14 19 15 20 16 10 21 11 27 106 21 107 108 109 110 21 111 28 112 28 10 113 29 11 11421 30 12 11521 32 13
NL6
Aug. 2002 ISSN 1346-6992 1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234 1234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890121234
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
PowerPoint プレゼンテーション
ICH 日本シンポジウム 2015 平成 27 年 7 月 23 日 M7 Addendum: DNA 反応性 ( 変異原性 ) 不純物の評価及び管理 国立医薬品食品研究所 変異遺伝部 本間正充 これまでの経緯と進捗状況 2010 年 6 月タリン会議 SC でトピック化決定 2010 年 11 月福岡対面会議 (1) ガイドラインタイトルの変更, 適用範囲, 一般原則 2012 年 11 月サンディエゴ対面会議
[ ] Table
![[ ] Table](/thumbs/96/130290982.jpg "[ ] Table")
[] Te P AP OP [] OP c r de,,,, ' ' ' ' de,, c,, c, c ',, c mc ' ' m' c ' m m' OP OP p p p ( t p t p m ( m c e cd d e e c OP s( OP t( P s s t (, e e s t s 5 OP 5 5 s t t 5 OP ( 5 5 5 OAP ABP OBP ,, OP t(
平成１９年度
1 2 3 4 H 3 H CC N + 3 O H 3 C O CO CH 3 CH O CO O CH2 CH 3 P O O 5 H H H CHOH H H H N + CHOH CHOH N + CH CH COO- CHOH CH CHOH 6 1) 7 2 ) 8 3 ) 4 ) 9 10 11 12 13 14 15 16 17 18 19 20 A A 0 21 ) exp( )
() 2
1 () 2 2 4 3 6,500 4 5 2 6 A B A B A B A B - A B 7 8 A B A B A B 9 JR JR 10 11 6 5 12 17 6 13 14 B A A B A B A B 2 1 8 15 8 16 17 9 18 3 4 5 mm mm 19 2 20 3 6 7 11 12 13 14 18 4 3 2 1 21 3 12 13 14 16
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
living essentials Japan 2014
living essentials Japan 2014 living essentials 3 3 11 TV / Hi-Fi 14 16 18 20 22 living essentials 24 USM 26 USM 30 USM 31 USM USM USM USM www.usm.com 1 W/D/H: 1523/523/740 mm A6 4 2 2 W/D/H: 2273/373/1090
42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =
![42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =](/thumbs/73/68712188.jpg "42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =")
3 3.1 3.1.1 kg m s J = kg m 2 s 2 MeV MeV [1] 1MeV=1 6 ev = 1.62 176 462 (63) 1 13 J (3.1) [1] 1MeV/c 2 =1.782 661 731 (7) 1 3 kg (3.2) c =1 MeV (atomic mass unit) 12 C u = 1 12 M(12 C) (3.3) 41 42 3 u
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
FCシリンダ
CAT. No. KS-570-01 C ujikura cylinder INDEX Page CS - - -22 CS - -3 - CD - -3 - CS -40-0 -4 CD -40-0 -4 CS - -20-3 CD - -20-3 CL-400 VCS CDR -400 1 ujikura Cylinders 2 3 4 C 0 3 0.0.7 00 CD 0 4 S0 P CS
gofman2.eps
2011 7 10 4 7 1 ICRP(2007) 5.7 10 2 Sv 1 1 13 (=4600 =11 =660 ) 10mSv 5.7 10 4 4600[] =2.6[] ICRP 0 1 licrp 1 2 1 DDREF ICRP(2007) (ICRP 2007, p.178) - (idem., p.174) 1Sv - (DDREF: dose and dose-rate effectiveness
2 A. Ramón y Cajal projectional brain map barrel Statview I I II II I I II II
1 B version1.3 A. B. C. D. E. F. G. H. 2 A. Ramón y Cajal projectional brain map barrel Statview I I II II I I II II . B-1-b 3 B-1-c 4 _m _m _m µ µ 5 Rieke et al. (1997) Spikes-Exploring the Neural Code
23 1 Section ( ) ( ) ( 46 ) , 238( 235,238 U) 232( 232 Th) 40( 40 K, % ) (Rn) (Ra). 7( 7 Be) 14( 14 C) 22( 22 Na) (1 ) (2 ) 1 µ 2 4
23 1 Section 1.1 1 ( ) ( ) ( 46 ) 2 3 235, 238( 235,238 U) 232( 232 Th) 40( 40 K, 0.0118% ) (Rn) (Ra). 7( 7 Be) 14( 14 C) 22( 22 Na) (1 ) (2 ) 1 µ 2 4 2 ( )2 4( 4 He) 12 3 16 12 56( 56 Fe) 4 56( 56 Ni)
人 々ばかりでなく 被 曝 時 年 齢 10~19 歳 のグループにおいても 減 少 しつつあるということである 20 歳 以
O~O~O~O~O~O~O~OOOO~O~O~OOOO~OOOO~OO O~~~O~O~O~O~OOOO~O~O~O~OOOOO~~ 人 々ばかりでなく 被 曝 時 年 齢 10~19 歳 のグループにおいても 減 少 しつつあるということである 20 歳 以 .~ 1) Y. Shimizu, H. Kato and W. J. Schull: Life span study report
untitled
24 2013116 1 2 23 24 24 (ICRP Publication 101, 57) ICRP Publ.101 Fig.2.1 25 26 ~ (1) (1) 2011311 2011315 葛 楢 () 2012315 2071315 1/2 27 137 Cs () X i = C ia Cs-137 V i i V i 137 Cs A Cs-137 C i A i = C
iii 1 1 1 1................................ 1 2.......................... 3 3.............................. 5 4................................ 7 5................................ 9 6............................
- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
ブック 1.indb
Graduate School of Policy and Management, Doshisha University 1 日本の府省における政策評価の実践とアカウンタビリティ 概要 1. はじめに 2001 1 2007 1 2015a 2 2 2010 3 Bovens 2007: 184 2016: 1 2015b: 5 PPBS Planning Programming Budgeting
VOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
(Jackson model) Ziman) (fluidity) (viscosity) (Free v
1) 16 6 10 1) e-mail: nishitani@ksc.kwansei.ac.jp 0. 1 2 0. 1. 1 2 0. 1. 2 3 0. 1. 3 4 0. 1. 4 5 0. 1. 5 6 0. 1. 6 (Jackson model) 8 0. 1. 7 10. 1 10 0. 1 0. 1. 1 Ziman) (fluidity) (viscosity) (Free volume)(
PAH ; XAD-2 ( XAD-2) PAH - LH-20 (HPLC) (SE-54 SE-52) ; -C18 HPLC PAH 1.3 PAH PAH PAH ( ) ( ) (, ) ( ) PAH : - bitumen ; - ; - ; - ; - ; - environment
No.202 Environmental Health Criteria No.202 (PAH) Selected Non-heterocyclic Polycyclic Aromatic Hydrocarbons ( 883 1998 ) 1. 1.1 (PAH) PAH PAH PAH 33 (31 PAH 2 ) ( 1) 8 10 PAH PAH 10-15 ; 1.2 ' ' 2 PAH
試験群設定による統計解析の選択法を表 4 に示した. 表 4. 検定手法の選択 単に両者の差は両側検定で, 強弱の問いかけは片側検定を採用する 群構成 比較対象 使用統計 2 群のみの設定 2 群間一回のみ Aspin-Welch の t- 検定 対照 (x 0 ), 低用量 (x 1 ), 中用量
第 9 章統計解析法の選定 1. 多重比較 範囲検定の群間組み合わせおよび検出力の比較 Dunnett および Duncan の多重範囲検定と比較しても Scheffé の検定は検出力が低いことがわかる. この理由は, 対比の組み合わせが Dunnett,Tukey および Duncan の検定に比較して多いためである ( 橋本,1997). 各検定の全対の比較で 5% を保証している. 表 1 に
05[和]_061-078[島田](責)山.indd
![05[和]_061-078[島田](責)山.indd](/thumbs/42/23101532.jpg "05[和]_061-078[島田](責)山.indd")
1858 1919 1. 1877 10 Studies in English and American Literature, No. 45, March 2010 2010 by the Engish Literary Society of Japan Women s University 62 1 1890 23 1 2 2 3 3 1891 1 1892 6 1892 9 1893 12 4
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
324 Fig. 1. Thermal data recorder and sensor protector Fig. 2. Outline of animal room. Fig. 3. Distribution of sensors
Exp. Anim. 26 (4), 323-329, 1977 Note Fluctuation and Distribution of Animal Room Temperature and the Temperature in Cages Joseph Akira YOSHIDA*, Tokutaro TAKAHASHI**, and Fumio *College of Science & Technology
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
（Ⅱ）化学物質の環境リスク初期評価（13物質）の結果
1,4-1 1,4- p- 1, 4-1, 4- CAS 123-91-1 C 4 H 8 O 2 88.11 2 1) 2) 11.80 3) 1- / (logp ow ) 101.1 760 mmhg 3) 1.033720 4) 37 mmhg25 5) 1 ppm = 3.60 mg/m 3 at 25, 6) -0.27 7) 8) 9) 3 7) 7) 10) 11) OH NO NO
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 13,996t 0% 2,379.3t 17.0% 4,630t 0% 532.4t 11.5% 72.9% 96.6% 3,000t 2.9% 3,000t 100.0% 20t BDF 75.0% 18t 90.0% 1,053t 1,053t 100.0% 1,068t 19.9% 854t 80.2% 670t 21.8% 670t
46-2-最終版.pdf
Jpn. J. Health Phys., 46 (2) 140 147 (2011) * 1 * 2 * 2 * 2 2010 10 22 2011 2 21 Development and Operational Results of a Real-time Remote Biological Information Monitoring Device for the Workers Wearing
δf = δn I [ ( FI (N I ) N I ) T,V δn I [ ( FI N I ( ) F N T,V ( ) FII (N N I ) + N I ) ( ) FII T,V N II T,V T,V ] ] = 0 = 0 (8.2) = µ (8.3) G
![δf = δn I [ ( FI (N I ) N I ) T,V δn I [ ( FI N I ( ) F N T,V ( ) FII (N N I ) + N I ) ( ) FII T,V N II T,V T,V ] ] = 0 = 0 (8.2) = µ (8.3) G](/thumbs/91/106215968.jpg "δf = δn I [ ( FI (N I ) N I ) T,V δn I [ ( FI N I ( ) F N T,V ( ) FII (N N I ) + N I ) ( ) FII T,V N II T,V T,V ] ] = 0 = 0 (8.2) = µ (8.3) G")
8 ( ) 8. 1 ( ) F F = F I (N I, T, V I ) + F II (N II, T, V II ) (8.1) F δf = δn I [ ( FI (N I ) N I 8. 1 111 ) T,V δn I [ ( FI N I ( ) F N T,V ( ) FII (N N I ) + N I ) ( ) FII T,V N II T,V T,V ] ] = 0
Z...QXD (Page 1)
Giesecke MacDonald and Marsh Virtanen et al. Bourdieu extra-institutional means NG National Labor Relations Board social movement organization Goodwin and Jasper Della Porta and Diani McAdam and Snow social
3 光毒性第三者評価報告書100924改
21 5 13 22 5 17 1 2 in vivo 24 in vivo 9 6 6 GLP 1 b 4 Acridine BMDM 4-t-butyl-4-methoxydibenzoylmethane CHD Chlorhexidine Bithionol CHD Bithionol in vivo in vivo b in vivo 70% b 5 in vitro 3T3-NRU 4 9
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
元素分析
: このマークが付してある著作物は 第三者が有する著作物ですので 同著作物の再使用 同著作物の二次的著作物の創作等については 著作権者より直接使用許諾を得る必要があります (PET) 1 18 1 18 H 2 13 14 15 16 17 He 1 2 Li Be B C N O F Ne 3 4 5 6 7 8 9 10 Na Mg 3 4 5 6 7 8 9 10 11 12 Al Si P
03J_sources.key
Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E
スライド 1
資料 2 発がん性評価の加速化 中期発がん性試験 : 二段階発がんモデル 日本バイオアッセイ研究センター 福島昭治 はじめに 医薬品 農薬 食品添加物等の開発にあたって 新規化合物の発がん性確認は極めて重要である すべての新規化学物質の発がん性を 腫瘍を指標とする長期発がん性試験で検討することは時間的 経済的観点より困難である ICH( 日米 EU 医薬品規制調和国際会議 1997) では 従来からの
1 I ( )
1 I. 3 1. 4 2. 6 3. 7 4. 8 4.1 8 4.2 ( ) 9 4.3 13 4.4 16 4.5 17 5. 19 5.1 20 5.2 25 5.3 33 6. 37 6.1 37 6.2 41 6.3 44 7. 46 7.1 46 7.2 47 II. 48 A 50 1 50 2 51 3 56 4 59 60 B 61 1 61 2 62 3 65 4 67 68
EPSON LP-S7500シリーズ 取扱説明書1 セットアップと使い方編
A B K L N N N N A B A N B N N A B D A B A B N N N N N N N N N N N K A B E C D F G N N N A B N N A A K B C D L E L L K F A B G N C N N C D B K E A B F AC N K G A B C H K D F E B G H K I G H L J
Microsoft Word - fiñfiÅ’«.doc
H N S O O H N H 3 C 3 µ µ µ µ GLP Douglas, W.W. (1980): Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Goodman and Gilman s The Pharmacological Basis of Therapeutics, 6th
好酸球性副鼻腔炎:診断ガイドライン（JESREC Study）
118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc
グルタルアルデヒドの測定手法検討結果
資料 1-5 グルタルアルデヒドの測定手法検討結果 1. はじめに 2. 予備試験 2-1. 捕集方法の決定 2-2. 検出方法の選択 (HPLC 法 ) 2-3-1. 前処理 2-3-2.HPLC 分析条件 3. 本試験 3-1. 捕集及び分析条件 3-2. 添加回収率 3-3. 捕集後のサンプラーの保存安定性 3-4. 検量線 ( 直線性 ) 3-5. 検出下限及び定量下限 3-6. 本分析方法の作業環境中
タワーフラックス観測マニュアル ver1.1b
2.2 CO2 H2O 2.2 CO 2 H 2 O Open-path CO 2 /H 2 O analyzer 2.2.1 CO 2 CO 2 CO 2 CO 2 CO 2 CO 2 mol-co 2 m 3 CO 2 ppm mol-co 2 mol-dry-air 1 CO 2 2.3 1 2 3 4 5 6 WPL Webb et al. 1980 1 3 4 6 Table 2.2-1
14 4 12 10 8 6 3 2 4 2 1 0 0 100200300400500600 100200300400500600700 0 0 100200300400500600 100200300400500600700 (ppm) (ppm) 7 4 6 5 4 3 3 2 2 1 1 0 0 100200300400500600 100200300400500600700 0 0 100200300400500600
untitled
b 0 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01% 0.1% 1% 10% 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01% 0.1% 1% 10% 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01%
税関分析25 年の進歩
25 1 25 40 27 25 27 32 25 CeEDTA 10) 11 1) Fe Al Zn EDTA 2) 12) n IR400 2N BT EDTA 14) e 15) 16) 17) 18) 3) Zn Cu 4) Mn 5) 6) 7) 8) 9 13) 2 24) X 56),57) 58) 25) 59) 60) X 61) X X 26) X 27),28),29) 62)
0 0 0 0............ PNEC.............................. PNECsed.................. 0 0 0 0 PNEC logpow. * Oncorhynchus mykisslc0. mg/l UFs0,000 0.000 mg/l0. µg/lpnec PNECwater PNECwater * Sangster, J. ()
untitled
1 2 1 2002 8 1 2003 11 1 152 2003 11 2 21 53 2003 12 24 4 54 2004 3 22 55 2004 4 9 56 2004 4 15 41 2004 4 15 2004 5 12 2004 5 19 2004 5 20 5 2004 12 16 58 2 2005 1 25 2005 8 23 5962 2005 8 26 2005 9 1
untitled
26 3 31 BDF BDF BDF FAME BDF BDF BDF BDF BDF BDF BDF BDF BDF FAME BDF BDF 80.0 97.0% BDF 120 330 0.8% 2.2% 1. 1 1-1 1 1-2 1 2. 2 2-1 2 2-2 5 2-3 6 3. BDF 7 3-1 7 3-2 7 3-3 14 3-4 JOY 21 3-5 32 3-6 39 3-7
資料２
OECD GLP OECD OECD 1960 30 OECD TG 2001 10 17 8 TG 202 208 TG 201 1984 6 TG 202 1984 4 TG 202 2000 10 TG 203 1992 7 TG 204 14 1984 4 TG 205 1984 4 TG 206 1984 4 TG 207 1984 4 TG 208 1984 4 2000 TG 209
JILPT Discussion Paper Series 07-04 2007 3 Spencer -1 - 1 2 1. 2. 3. 3 4. 3 1. 2. 3. 4. 4 1. 2. 3. 5 1. 2. 3. 4. 5. 6-2 - 1 1990 1 2 JILPT 3 1 2005 2005 2003 2 2003 3-3 - Spencer 2 1. 2000 2002 underlying